Skip to main content
. 2022 Sep 30;13:1020123. doi: 10.3389/fphar.2022.1020123

FIGURE 1.

FIGURE 1

Primary Outcome. (A) Mean log SARS-CoV-2 viral RNA in placebo compared to atovaquone over the 10-days trial period. (B) Viral load decline in placebo and atovaquone groups. No statistically significant difference was detected between the two groups.